News | March 31, 2021
Investment opportunities in India’s healthcare sector: NITI Aayog
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
Lonza Specialty Ingredients has become LifeClean’s first strategic industrial partner.
The collaboration of two strong partners, CELLINK and UPM, builds confidence in making these treatments into an industrial and clinical standard, applied in a wider setting instead of remaining only within few hospitals.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
Bharat Biotech expects to share further details of the trial results as additional data become available.
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.
India business grew 11.8% YoY vs mid-single digit industry growth.
Subscribe To Our Newsletter & Stay Updated
